Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab α(CMAB007) vs Xolair in Chronic Spontaneous Urticaria
NCT06365879Phase 3Completed
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- Jun 2024
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in chronic spontaneous urticaria (CSU), sponsored by Taizhou Mabtech Pharmaceutical. Started Jun 2024; status: completed.
02
Drugs
omalizumab
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06365879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365879.